Association Between Lipophilic Beta-Blockers and Depression in Diabetic Patients on Chronic Dialysis.

Beta-blockers depressive symptoms diabetes diabetic kidney disease dialysis

Journal

Clinical medicine insights. Endocrinology and diabetes
ISSN: 1179-5514
Titre abrégé: Clin Med Insights Endocrinol Diabetes
Pays: United States
ID NLM: 101578235

Informations de publication

Date de publication:
2022
Historique:
received: 13 05 2022
accepted: 19 07 2022
entrez: 5 9 2022
pubmed: 6 9 2022
medline: 6 9 2022
Statut: epublish

Résumé

Depression is associated with lower quality of life and increased risk of mortality. The prevalence of depression in chronic dialysis patients, as well as in patients with diabetes, is more than 20%. It is debated whether use of beta-blockers increases the risk of depression. Therefore, we examined in chronic dialysis patients with and without diabetes, the association between beta-blockers and depressive symptoms. Data were collected from the DIVERS-I study, a multicentre prospective cohort among chronic dialysis patients in the Netherlands. Depressive symptoms were assessed with the Beck Depression Inventory (BDI-II). We defined depressive symptoms as a BDI-II score ⩾16. The cross-sectional association at baseline between depressive symptoms and beta-blocker use in chronic dialysis patients, was studied by multivariable logistic regression adjusted for potential confounders. We included 684 chronic dialysis patients, of whom 43% had diabetes mellitus, and 57% used a beta-blocker of which 97% were lipophilic. After multivariable adjustment, the OR (95% CI) for depressive symptoms in patients with compared to without diabetes was 1.41 (1.00-1.98), and in beta-blocker users compared to non-users 1.12 (0.80-1.56), respectively. Dialysis patients with diabetes and beta-blocker use compared to those without diabetes and not using beta-blockers had an OR of 1.73 (1.12-2.69) for depressive symptoms. The association was stronger in dialysis patients with diabetes and lipophilic beta-blocker use with an OR of 1.77 (1.14-2.74). We found a possible association between lipophilic beta-blocker use and depressive symptoms in chronic dialysis patients with diabetes.

Sections du résumé

Background UNASSIGNED
Depression is associated with lower quality of life and increased risk of mortality. The prevalence of depression in chronic dialysis patients, as well as in patients with diabetes, is more than 20%. It is debated whether use of beta-blockers increases the risk of depression. Therefore, we examined in chronic dialysis patients with and without diabetes, the association between beta-blockers and depressive symptoms.
Methods UNASSIGNED
Data were collected from the DIVERS-I study, a multicentre prospective cohort among chronic dialysis patients in the Netherlands. Depressive symptoms were assessed with the Beck Depression Inventory (BDI-II). We defined depressive symptoms as a BDI-II score ⩾16. The cross-sectional association at baseline between depressive symptoms and beta-blocker use in chronic dialysis patients, was studied by multivariable logistic regression adjusted for potential confounders.
Results UNASSIGNED
We included 684 chronic dialysis patients, of whom 43% had diabetes mellitus, and 57% used a beta-blocker of which 97% were lipophilic. After multivariable adjustment, the OR (95% CI) for depressive symptoms in patients with compared to without diabetes was 1.41 (1.00-1.98), and in beta-blocker users compared to non-users 1.12 (0.80-1.56), respectively. Dialysis patients with diabetes and beta-blocker use compared to those without diabetes and not using beta-blockers had an OR of 1.73 (1.12-2.69) for depressive symptoms. The association was stronger in dialysis patients with diabetes and lipophilic beta-blocker use with an OR of 1.77 (1.14-2.74).
Conclusions UNASSIGNED
We found a possible association between lipophilic beta-blocker use and depressive symptoms in chronic dialysis patients with diabetes.

Identifiants

pubmed: 36061232
doi: 10.1177/11795514221119446
pii: 10.1177_11795514221119446
pmc: PMC9434677
doi:

Types de publication

Journal Article

Langues

eng

Pagination

11795514221119446

Informations de copyright

© The Author(s) 2022.

Déclaration de conflit d'intérêts

Competing Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Références

Arch Gen Psychiatry. 1961 Jun;4:561-71
pubmed: 13688369
Blood Purif. 2017;43(1-3):226-234
pubmed: 28114133
J Am Soc Nephrol. 2015 Apr;26(4):774-6
pubmed: 25359873
Psychol Med. 2021 May;51(7):1183-1191
pubmed: 31973782
Am J Epidemiol. 1976 May;103(5):506-11
pubmed: 1274952
Nephrol Dial Transplant. 2007 May;22 Suppl 2:ii5-21
pubmed: 17507427
Am J Kidney Dis. 2012 May;59(5):670-81
pubmed: 22206743
Kidney Int. 2013 Jul;84(1):179-91
pubmed: 23486521
Fam Med. 2014 Jun;46(6):447-53
pubmed: 24911300
Am J Kidney Dis. 2014 Apr;63(4):623-35
pubmed: 24183836
Am J Kidney Dis. 1995 Aug;26(2):353-61
pubmed: 7645541
J Clin Psychopharmacol. 2011 Feb;31(1):45-50
pubmed: 21192142
Am J Epidemiol. 1980 Oct;112(4):467-70
pubmed: 7424895
Nephrol Dial Transplant. 2001 Jun;16(6):1120-9
pubmed: 11390709
Nephrol Dial Transplant. 2008 Aug;23(8):2653-9
pubmed: 18323520
J Am Coll Cardiol. 2006 Dec 5;48(11):2209-14
pubmed: 17161247
BMC Psychol. 2017 Jan 12;5(1):1
pubmed: 28081723
Am J Kidney Dis. 2019 Aug;74(2):158-166
pubmed: 31027882
Hippokratia. 2012 Jul;16(3):205-14
pubmed: 23935284
J Clin Epidemiol. 2012 May;65(5):488-92
pubmed: 22342262
Psychosom Med. 2012 Oct;74(8):854-60
pubmed: 23006428
Epidemiology. 1992 Sep;3(5):452-6
pubmed: 1391139
Curr Diab Rep. 2010 Dec;10(6):396-405
pubmed: 20878274
BMC Res Notes. 2009 Jun 15;2:105
pubmed: 19527493
Am J Epidemiol. 2018 Nov 1;187(11):2470-2480
pubmed: 30060004
J Psychosom Res. 2010 Oct;69(4):363-70
pubmed: 20846537
J Hum Hypertens. 2020 Nov;34(11):787-794
pubmed: 32001828
Mol Psychiatry. 2019 Jan;24(1):18-33
pubmed: 29453413
BMJ. 2009 Jun 29;338:b2393
pubmed: 19564179
Kidney Int. 2002 Jul;62(1):199-207
pubmed: 12081579
JAMA. 2002 Jul 17;288(3):351-7
pubmed: 12117400
Clin Sci (Lond). 2013 Feb;124(3):139-52
pubmed: 23075333
J Affect Disord. 1987 Sep-Oct;13(2):119-30
pubmed: 2890677
BMJ Open Diabetes Res Care. 2016 Dec 15;4(1):e000310
pubmed: 28074142
Diabet Med. 2006 Nov;23(11):1165-73
pubmed: 17054590
Am J Hypertens. 2003 Sep;16(9 Pt 2):7S-12S
pubmed: 14511896
Kidney Int. 2009 Apr;75(7):677-81
pubmed: 19190674
Psychosom Med. 2019 Sep;81(7):649-658
pubmed: 31232914

Auteurs

Robin Lengton (R)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Robbert W Schouten (R)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Nephrology, OLVG hospital, Amsterdam, The Netherlands.

Els Nadort (E)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Psychiatry, OLVG hospital, Amsterdam, The Netherlands.

Elisabeth Fc van Rossum (EF)

Department of Internal Medicine, Division of Endocrinology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands.

Friedo W Dekker (FW)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.

Carl Eh Siegert (CE)

Department of Nephrology, OLVG hospital, Amsterdam, The Netherlands.

Ellen K Hoogeveen (EK)

Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Department of Nephrology, Jeroen Bosch Hospital, Den Bosch, The Netherlands.

Classifications MeSH